Correction: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

更正：达沃塞替普（ALPN-202）是一种 PD-L1 依赖性 CD28 共刺激剂和双重 PD-L1/CTLA-4 抑制剂，其作为单药疗法以及与帕博利珠单抗联合疗法治疗晚期实体瘤的 I 期研究（NEON-1 和 NEON-2）。